Trust Signals
Key Takeaways
- Pinealon is a tripeptide with the sequence Glu-Asp-Arg and an approximate molecular weight of 389 daltons, placing it in the "short bioregulator peptide" class developed by Vladimir Khavinson's group at the Saint Petersburg Institute of Bioregulation and Gerontology.
- The overwhelming majority of published pinealon research is in vitro or rodent-based and originates from a single Russian research group, which creates serious replication and independence concerns that most vendor pages never mention.
- Pinealon's proposed mechanism, direct gene-promoter interaction enabled by its small size, has some cell-biology support but has not been confirmed by an independent laboratory with human pharmacokinetic data.
- When you buy pinealon for sale online, a lot-specific COA showing HPLC purity above 98% plus mass spectrometry sequence confirmation is the minimum acceptable quality standard; anything less is unverifiable.
- Reconstituted pinealon degrades meaningfully over weeks at refrigerator temperature due to hydrolysis at the aspartic acid residue and oxidation at arginine; lyophilized storage at minus 20 degrees Celsius is the only evidence-consistent preservation method.
What Is Pinealon and Should You Buy It?
If you want to buy pinealon, understand this first: it is a three-amino-acid synthetic peptide (Glu-Asp-Arg) with a neuroprotection research profile built almost entirely on cell and rodent studies from one Russian institute. No Western-standard RCT confirms its effects in humans. It is a legitimate research compound with interesting mechanistic hypotheses, not a proven therapeutic.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What is pinealon peptide exactly?
- What does the evidence actually show?
- How does pinealon work at the molecular level?
- What most pages about pinealon get wrong
- Can pinealon reach the brain?
- How does pinealon compare to alternatives?
- Chemistry behind storage rules
- How to buy pinealon peptide and judge the source
- Dosing and protocol context from existing research
- Frequently asked questions
- Sources
What Is Pinealon Peptide Exactly?
Pinealon belongs to a class of short peptides called "cytomedines" or "peptide bioregulators" developed by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology beginning in the 1970s under Soviet military-funded aging research. The program isolated short peptides from animal tissues and synthesized them as potential organ-specific regulators.
Pinealon was developed to target neural and pineal gland function. Its amino acid sequence is Glutamic acid, Aspartic acid, Arginine (EDR in single-letter code). Molecular weight is approximately 389 daltons. At that size, it is small enough that researchers have proposed it may translocate across cell membranes and interact with DNA regulatory regions, a property attributed to Khavinson's broader peptide class in his group's publications.
It is distinct from Epithalon (Epitalon, AEDG), which is a four-amino-acid peptide from the same program with a different proposed primary target (telomerase activation). Pinealon's focus in the literature is neuroprotection, circadian rhythm support, and mitigation of oxidative stress in neural tissue.
What Does the Evidence Actually Show? Evidence Ledger
The table below grades the major claimed effects of pinealon by the best evidence type available, its directional finding, and an honest confidence rating. This is the information most pinealon for sale pages hide.
| Claimed Effect | Best Evidence Type | Direction | Confidence | Key Caveat |
|---|---|---|---|---|
| Neuroprotection under oxidative stress | In vitro (cell culture), rodent models | Positive in models | Low | Not replicated by independent labs; no human data |
| Modulation of circadian gene expression | In vitro, Khavinson group publications | Positive in models | Very Low | Single-group origin; no independent confirmation |
| Anti-aging effects on neural tissue | Rodent lifespan and histology studies | Positive trend in aged rodents | Low | Rodent aging models frequently fail human translation |
| Improved cognitive function | Animal behavioral studies | Positive in some models | Very Low | No human cognition RCT identified in Western literature |
| Blood-brain barrier penetration | Proposed mechanism, animal pharmacokinetics | Plausible but unconfirmed | Very Low | No human PK data published in peer-reviewed Western journals |
| Safety in humans at research doses | Russian clinical reports, no placebo RCT | No serious adverse events reported | Low | Absence of reported harm is not proof of safety; reporting rigor uncertain |
How Does Pinealon Work at the Molecular Level?
Khavinson's group has published a proposed gene-regulatory mechanism for pinealon and related short peptides. The core hypothesis, supported by computational docking studies and some cell-based reporter assays in their publications, is that the Glu-Asp-Arg tripeptide can interact with specific gene promoter sequences, particularly those governing genes involved in oxidative stress response and circadian timing such as CLOCK, BMAL1, and antioxidant enzyme genes.
The size argument is important here. At roughly 389 daltons and three residues, pinealon is far below the typical threshold where peptide transport becomes size-prohibitive. Khavinson's group has argued in publications including work in the Bulletin of Experimental Biology and Medicine and Advances in Gerontology that such short peptides can penetrate nuclear membranes and bind to promoter regions in a sequence-complementary manner, acting as what they call "gene expression regulators."
What this mechanism does NOT prove, and this matters: computational docking and cell-culture binding assays do not establish that pinealon achieves these interactions at physiologically meaningful concentrations in a living human brain. The gap between "binds in silico" and "produces a measurable clinical effect in humans" is the gap that human pharmacokinetic and dose-response studies are supposed to close, and those studies have not been done to Western regulatory standards.
Specific published data points from Khavinson's group include claims of upregulation of antioxidant-related gene expression in neuronal cell models and modulation of melatonin-pathway-adjacent gene activity, but the precise fold-changes and p-values in those studies should be interpreted with the single-group, non-independent caveat clearly in mind.
What Most Pinealon Pages Get Wrong
Bioavailability is treated as solved when it is not: Most pinealon for sale listings describe it as a "brain peptide" as though CNS penetration is confirmed. It is not. Intranasal administration is proposed as a route to improve CNS delivery, and some animal data supports partial brain penetration via this route for small peptides generally, but lot-specific human pharmacokinetic data for pinealon does not exist in accessible peer-reviewed literature.
Purity standards are never explained: The tripeptide synthesis route for Glu-Asp-Arg is relatively straightforward by modern solid-phase peptide synthesis, but common impurities include deletion sequences (dipeptides missing one residue), racemized amino acid variants (D-form instead of L-form), oxidized arginine species, and residual TFA (trifluoroacetic acid) from synthesis. None of these impurities appear on a basic label. They require HPLC and mass spectrometry to detect.
Can Pinealon Reach the Brain? The Penetration Question
This is the most practically important question for anyone considering buying pinealon peptide, and the honest answer is: possibly, via intranasal administration, but unconfirmed in humans by pharmacokinetic measurement.
The blood-brain barrier restricts most peptides. For very small peptides under roughly 500 to 600 daltons, some passive transcellular diffusion is plausible, and intranasal delivery bypasses part of the barrier by using the olfactory pathway. Rodent models of intranasal small-peptide delivery have demonstrated measurable CNS penetration for some compounds in this size range. Whether pinealon specifically achieves therapeutically relevant CNS concentrations in humans via any available route is an open question without a human PK answer.
Oral administration almost certainly results in extensive proteolytic degradation in the GI tract before systemic absorption. Peptides of this size and without specific protective modifications are generally poor oral bioavailability candidates, though some cell-penetrating tripeptides have demonstrated unexpected gut-wall absorption in research models. This is an area where honest uncertainty is warranted rather than confident claims in either direction.
Honest Head-to-Head: Pinealon vs. Real Alternatives
If neuroprotection or cognitive support is the research goal, pinealon competes against other approaches with stronger or weaker evidence profiles. This table concedes where pinealon loses.
| Compound or Approach | Mechanism Evidence Level | Human RCT Data? | CNS Penetration Confirmed? | Where Pinealon Wins | Where Pinealon Loses |
|---|---|---|---|---|---|
| Pinealon (Glu-Asp-Arg) | Cell and rodent, single group | No (Western standard) | Not confirmed in humans | Novelty; very low apparent toxicity in reports; short sequence | Evidence depth; replication; PK data |
| Epithalon (Epitalon, AEDG) | Cell and rodent; some Russian human reports | Limited Russian clinical reports only | Not confirmed by Western PK | More published human observation data (though same single-group caveat) | Same fundamental replication problem as pinealon |
| Semax (ACTH 4-10 analog) | Better rodent data; some human stroke trial data from Russia | Yes, limited Russian RCTs in stroke | Intranasal PK studied more than pinealon | Meaningfully larger human evidence base for acute neuroprotection | Not FDA-approved; still limited Western replication |
| Melatonin | Strong mechanistic and human RCT base | Yes, many Western RCTs | Yes, confirmed | Pinealon wins nothing on circadian evidence vs. melatonin | Pinealon loses on every evidence dimension for circadian use |
| Omega-3 fatty acids (DHA) | Strong mechanistic; large human cohort and RCT data | Yes, large Western RCTs | Yes, CNS incorporation confirmed | Pinealon is novel; different mechanism | Pinealon has far less evidence for any neuroprotective endpoint |
The Chemistry Behind Pinealon Storage Rules
Most vendor pages say "store frozen" without explaining why. The chemistry matters if you want to preserve what you paid for.
Aspartic acid residue hydrolysis: Aspartic acid (Asp) in peptide sequences is particularly prone to two degradation reactions. First, it undergoes succinimide intermediate formation at neutral to mildly alkaline pH, which leads to isomerization and epimerization, producing a D-Asp residue instead of L-Asp. This changes the three-dimensional shape of the peptide. Second, the peptide bond adjacent to Asp is more susceptible to hydrolysis than most other residues, meaning peptide backbone cleavage is more likely at this position under aqueous conditions over time. This is why reconstituted pinealon in solution degrades faster than lyophilized powder: water is required for hydrolysis.
Arginine oxidation: The guanidinium group of arginine is susceptible to oxidation, particularly in the presence of metal ions, peroxides, or reactive oxygen species. Oxidized arginine residues change binding characteristics and may abolish or alter biological activity. Storing peptides in amber vials, avoiding repeated freeze-thaw cycles, and using metal-free, deoxygenated reconstitution water reduces this risk.
Why lyophilized form at minus 20 degrees Celsius: Lyophilization removes water, eliminating the hydrolysis requirement. Cold temperature slows oxidation kinetics and residual chemical reaction rates. Desiccation keeps the powder below the critical moisture activity threshold where degradation accelerates. A lyophilized vial that has never been reconstituted, stored correctly, should retain structural integrity for at least a year, though lot-specific stability data from your vendor is the only reliable source for actual shelf-life numbers.
TFA residue gotcha: Most peptides synthesized by standard Fmoc solid-phase synthesis carry residual trifluoroacetic acid from the cleavage step. TFA forms a salt with basic residues like arginine. At high enough residual concentrations, TFA can be cytotoxic in cell assays, potentially confounding in vitro research results. A vendor who performs a counter-ion exchange step (often to acetate salt) or documents TFA residual levels on the COA is providing a meaningfully better product for research purposes.
How to Buy Pinealon Peptide and Judge the Source
When you search "pinealon peptide for sale," you will find dozens of vendors. Most of them cannot be distinguished on product pages alone. Here is what to actually check.
Minimum COA Requirements
| Test | What It Confirms | Acceptable Result | Red Flag |
|---|---|---|---|
| HPLC purity | Percentage of the target compound relative to total UV-absorbing material | Greater than or equal to 98% | No HPLC data; "greater than 95%" without a chromatogram |
| Mass spectrometry (ESI-MS or MALDI) | Confirms actual molecular weight matches Glu-Asp-Arg (expected approximately 389 Da) | Observed mass within 1 Da of theoretical | No MS data; only HPLC provided |
| Amino acid analysis or sequence confirmation | Confirms correct amino acid composition and sequence | Correct ratio of Glu, Asp, Arg | Not performed |
| Endotoxin (LAL test) | Bacterial lipopolysaccharide contamination from synthesis | Less than 1 EU/mg for research use | Not tested; absence of data |
| Residual TFA or counter-ion | Cytotoxic contaminant from SPPS synthesis | Less than 0.1% or counter-ion exchanged to acetate | Not disclosed |
| Lot-specific COA | Tests apply to the actual lot you are buying, not a generic batch | Lot number matches your order | Generic or undated COA; no lot number |
What Degraded Pinealon Looks Like
Lyophilized powder should be white to off-white, free-flowing, and dissolve cleanly in aqueous solution within seconds. Yellow or tan discoloration suggests oxidation. Clumping or caking that does not dissolve fully suggests moisture exposure and partial hydrolysis. A reconstituted solution should be clear and colorless; cloudiness or visible particles indicate degradation or contamination. If any of these signs are present, do not use the material for research and contact the vendor about the lot.
Dosing and Protocol Context From Existing Research
Because no human dose-finding RCT exists for pinealon, any "protocol" circulating online is extrapolated from animal studies or Russian bioregulator clinical observations with limited methodological transparency. This section presents what exists in the literature, not a recommendation.
Rodent studies from Khavinson's group have used doses described in the microgram per kilogram range, administered intranasally or by injection. Human bioregulator protocols described in Russian gerontology literature typically involve very low microgram-level doses given in cyclical patterns (described as courses of weeks followed by off periods), though specific validated dose-response relationships are not established by controlled trial.
The practical dosing implication: because no human PK data exists for pinealon, determining what dose achieves any target tissue concentration in a human is currently impossible. Anyone presenting a specific human dose as "validated" is extrapolating from animal data or Russian observational reports without a rigorous pharmacological basis. That is a meaningful distinction from compounds where human PK and dose-response have been formally studied.
Frequently Asked Questions
What is pinealon and what is it made of?
Pinealon is a synthetic tripeptide composed of three amino acids: glutamic acid, aspartic acid, and arginine (sequence Glu-Asp-Arg). It was developed in Russia as part of the Khavinson peptide bioregulator program and is marketed primarily as a neuroprotective and anti-aging research compound.
Where can you buy pinealon peptide for research?
Pinealon for sale is available from several peptide research chemical suppliers online. Quality varies widely. Key indicators of a reliable vendor include third-party HPLC purity data above 98%, independent mass spectrometry confirmation of sequence identity, and transparent COA documentation traceable to an accredited analytical lab.
What does the evidence actually say about pinealon?
The bulk of pinealon research is in vitro cell work and rodent studies, primarily from Russian research groups. Very few independent, placebo-controlled human trials exist in peer-reviewed Western literature. Effects seen in cell and animal models include neuroprotection under oxidative stress and modulation of gene expression linked to circadian regulation, but these findings have not been confirmed in rigorous human RCTs.
How is pinealon believed to work mechanistically?
Pinealon is proposed to act as a gene-regulatory peptide that can penetrate cell membranes and interact with gene promoter regions. Research from Khavinson's group suggests it may modulate expression of genes involved in circadian function, oxidative stress response, and neuroprotection. The tripeptide's small size (roughly 389 daltons) is central to this proposed nuclear access, though independent confirmation of the exact binding mechanism is limited.
Can pinealon cross the blood-brain barrier?
Animal studies suggest small peptides in pinealon's molecular weight range can achieve some CNS penetration, and Khavinson's research proposes intranasal or sublingual delivery as routes to improve access. However, direct human pharmacokinetic data confirming blood-brain barrier penetration and meaningful CNS concentrations does not exist in peer-reviewed Western literature.
What is the typical dosing protocol used in research settings?
Animal and observational research protocols have used doses in the range of roughly 1 to 10 micrograms per kilogram in rodent studies, often given intranasally or by injection. Human protocols discussed in Russian bioregulator literature describe very low microgram-range doses. No peer-reviewed human dose-finding trial has established a validated safe and effective dose for any indication.
How should pinealon be stored after reconstitution?
Lyophilized pinealon powder is best stored at minus 20 degrees Celsius in a dry, dark environment. Once reconstituted in bacteriostatic water, it should be refrigerated at 2 to 8 degrees Celsius and used within a few weeks. Reconstituted peptide degrades faster than lyophilized powder due to hydrolysis and oxidation at the aspartic acid and arginine residues. Freeze-thaw cycles accelerate degradation.
How does pinealon compare to epithalon or other Khavinson peptides?
Epithalon (Epitalon) has a modestly larger published evidence base including some human clinical data from Russian literature, and its proposed telomerase-activation mechanism has received more independent commentary. Pinealon has a narrower neuroprotection-focused research profile with almost entirely cell and rodent evidence. Neither has completed a Western-standard phase II or phase III RCT.
What are the main risks of buying pinealon peptide online?
The primary risks are product impurity, incorrect sequence, wrong molecular weight, and bacterial endotoxin contamination. Without HPLC, mass spec, and endotoxin testing data on a lot-specific COA, you cannot verify what you are buying. Counterfeit or mislabeled peptides are common in the research chemical market.
Is pinealon legal to buy?
In most Western countries including the United States, pinealon is not an FDA-approved drug and is not scheduled as a controlled substance. It is typically sold as a research chemical for laboratory use only, not for human consumption. Legal status can differ by jurisdiction and may change, so buyers should verify local regulations.
What does a degraded pinealon sample look like?
Degraded lyophilized pinealon may show visible yellowing of the powder, clumping or caking that does not dissolve cleanly, or a reconstituted solution that appears cloudy or has visible particulate matter. Any of these signs suggest oxidation, moisture exposure, or thermal degradation and the sample should not be used.
Sources
- Khavinson VKh, Linkova NS, Kvetnoy IM, et al. Neuroprotective and Geroprotective Properties of the Peptide Bioregulators. Advances in Gerontology. Various years. [Multiple publications from the Saint Petersburg Institute of Bioregulation and Gerontology; searchable on PubMed by author Khavinson VKh.]
- Khavinson V, Diomede F, Mironova E, et al. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules. 2020;25(3):609. PMC7037063. [Context on Khavinson short-peptide gene-regulatory hypothesis applicable to pinealon class.]
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;135(6):590-592. [Context on Khavinson peptide bioregulator research program.]
- Peptide Chemistry and Stability: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research. 2010;27(4):544-575. [General peptide degradation pathways including Asp isomerization and Arg oxidation.]
- Aspartic acid degradation chemistry: Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Journal of Biological Chemistry. 1987;262(2):785-794. [Classic reference on Asp/Asn instability in peptides.]
- Strand R, Tafil-Klawe M. Blood-brain barrier and peptide transport. General review of molecular weight and lipophilicity constraints. Multiple textbook and review sources; see Pardridge WM. Drug Delivery to the Brain. Springer, 2022.
- TFA cytotoxicity in cell assays: Sigma-Aldrich/Merck technical documentation on TFA counter-ion in synthetic peptides and recommendations for cell biology use. [Accessible via vendor technical resources.]
- Semax human stroke evidence: Makhinson MV, et al. Published Russian clinical trial data on Semax in cerebrovascular disease; see PubMed searches for "Semax stroke RCT" for available indexed studies.
- Endotoxin testing standards: United States Pharmacopeia, Chapter 85, Bacterial Endotoxins Test. USP-NF. [Standard reference for endotoxin limits in parenteral research preparations.]
- Melatonin circadian RCT evidence: Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8(5):e63773.
Footer Disclaimers
Platform: FormBlends is an educational and research-literacy platform. Content on this page is written for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Consult a licensed healthcare provider before making any health-related decisions.
Research Compound: Pinealon is sold as a research chemical for laboratory and scientific research use only. It is not approved by the FDA or any equivalent regulatory authority as a drug, food supplement, or medical treatment. It is not intended for human consumption.
Results: No results described on this page should be interpreted as typical or guaranteed outcomes. Evidence ratings reflect the current state of published research and are subject to revision as new data emerges. Individual responses to any compound vary and are unpredictable without clinical evaluation.
Trademark: "Pinealon" is used as a common research-chemical descriptor. FormBlends makes no claim over this term and references it solely for search and educational clarity. All third-party brand names, compound names, and institutional names referenced belong to their respective owners.